Evidence map›Paper›PMID 31798645›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2019

Bronchoscopy-guided bronchial epithelium sampling as a tool for selecting the optimal biologic treatment in a patient with severe asthma: a case report.

Chin-Wei Kuo, Xin-Min Liao, Yi-Ching Huang, Han-Yu Chang, Chi-Chang Shieh

3 registry-linked trialsOpen access · goldAbstract readCase Reports
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04612556 unknown statusnot on this mapstarted 2021, after this paper: background citation

Efficacy of Mepolizumab in Patients With Late-onset Severe Eosinophilic Asthma and Fixed Obstruction

TypeobservationalSponsorAristotle University Of ThessalonikiRan2021 to 2025Enrolled45ConditionsAsthma, Eosinophilic, Severe Asthma, Late-Onset AsthmaArmsMepolizumab 100 MG [Nucala]
NCT05708300 recruitingnot on this mapstarted 2024, after this paper: background citation

Novel Insight in pathologiCal and clinicAl Attributes in Response to mepoLizumab Treatment in Patients With Chronic rhInosinusitis With Nasal pOlyPs With or Without bronchIal Asthma on a Long-term Basis (CALIOPI STUDY)

TypeobservationalSponsorAristotle University Of ThessalonikiRan2024 to 2027Enrolled57ConditionsChronic Rhinosinusitis With Nasal Polyps, AsthmaArmsMepolizumab 100 MG [Nucala]
NCT06288516 phase4unknown statusnot on this mapstarted 2024, after this paper: background citation

BenRalizumab Effect on Airway Remodeling in Severe Eosinophilic asTHmatics

TypeinterventionalSponsorAristotle University Of ThessalonikiRan2024 to 2026Enrolled45ConditionsAsthma, Eosinophilic, Airway RemodelingArmsBenralizumab 30 mg/ml
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chin-Wei Kuo1Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Xin-Min Liao1Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Yi-Ching Huang3Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Han-Yu Chang1Division of Chest Medicine, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Chi-Chang Shieh2Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan, 70403 Taiwan.
National Cheng Kung University Hospital · TWNational Cheng Kung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are numerous biologics for treating patients with severe asthma. A cost-effective method for selecting the most appropriate biologic therapy for a patient is thus important. Bronchoscopy-guided bronchial epithelium sampling may provide information for determining the type of inflammation in the airways of severe asthma patients through immunochemical analysis and thus help clinicians select the correct biologics. CASE PRESENTATION: We report the case of a female with severe asthma and eosinophilia who initially responded to omalizumab treatment. She developed an allergic reaction after four injections of omalizumab. Omalizumab desensitization was successfully conducted. To select an appropriate biologic agent after this hypersensitivity episode, we performed bronchoscopy-guided bronchial epithelium sampling. Omalizumab treatment was resumed based on the findings of immunohistochemical staining after a successful desensitization procedure, leading to long-term control of her severe asthma.

conclusionsSelecting an adequate biologic agent for severe, uncontrolled asthma is a challenge in clinical medical practice. Although phenotypes, blood eosinophils, and serum IgE levels have been proposed for use as a reference, there is a dissociation between the blood immune-cell level and the airway epithelium immune reaction, as confirmed in previous studies. Airway epithelium immunohistochemistry staining for targeted immune cells has been used to determine various types of airway inflammation; however, this technique is rarely used in a clinical setting. Previous studies have revealed the relative safety of performing bronchoscopy biopsies for patients with severe asthma. Among the sampling techniques used for tissue diagnosis, including nasal biopsies, nasal or bronchial brushing, and bronchoalveolar lavage, bronchoscopy-guided bronchial epithelium sampling provides more accurate information about the epithelial and inflammatory cells in the tissue context. It is thus a powerful tool for selecting the most suitable biologics in difficult clinical conditions.

Indexed as

Bronchial epithelium samplingOmalizumabSevere asthma

Identifiers

PMID31798645
PMCPMC6881985
OpenAlexW2989833645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.